Prolia 60 mg contains denosumab, a RANK ligand (RANKL) inhibitor prescribed for osteoporosis and selected conditions that cause bone loss. The main Prolia 60 mg uses include reducing fracture risk in postmenopausal women and men with osteoporosis, treating glucocorticoid-induced osteoporosis, and preventing bone loss associated with certain prostate and breast cancer treatments. Prolia is a prescription medicine and requires planned dosing, calcium and vitamin D support, and medical monitoring.
What are Prolia 60 mg uses?
Prolia 60 mg is used to treat osteoporosis in adults who have a high risk of fractures. Prolia reduces bone breakdown by blocking RANKL, a protein that activates osteoclasts, the cells responsible for bone resorption. Lower bone resorption helps maintain or improve bone mineral density and reduces fracture risk.
The approved uses include:
- Postmenopausal osteoporosis in women at high fracture risk, including reduction of vertebral, nonvertebral, and hip fractures.
- Osteoporosis in men at high fracture risk.
- Glucocorticoid-induced osteoporosis in men and women at high fracture risk who use long-term systemic corticosteroids.
- Bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
- Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
Postmenopausal osteoporosis can develop without obvious early symptoms, so understanding osteoporosis symptoms in women and discussing fracture risk with a healthcare professional can help determine whether further evaluation is needed.
These indications make Prolia an important osteoporosis treatment when a clinician determines that denosumab is appropriate for your fracture risk and medical history.
How does Prolia 60 mg work?
Prolia works by binding to RANKL and preventing RANKL from activating osteoclasts. Osteoclasts normally break down old bone tissue as part of bone remodeling. By reducing osteoclast activity, denosumab slows bone resorption and helps maintain stronger bones.
Prolia does not work like a calcium supplement. Calcium and vitamin D provide nutrients required for normal bone metabolism, while denosumab reduces the cellular process that breaks down bone. Your healthcare professional may recommend calcium and vitamin D throughout treatment based on your individual needs.
Prolia 60 mg dosage and injection frequency
The standard Prolia dosage is 60 mg given as one subcutaneous injection once every 6 months. The Prolia 60 mg/ml syringe contains 60 mg of denosumab in 1 mL of solution. A healthcare professional administers Prolia in the upper arm, upper thigh, or abdomen.
Prolia injection frequency matters because the treatment schedule is based on a 6-month interval. Mark your next injection date and contact your healthcare provider before the scheduled date if an appointment problem occurs.
If you miss a Prolia dose, receive the injection as soon as possible. The next 6-month interval starts from the date of the delayed injection rather than from the original appointment date.
Do not change the dose or injection interval yourself. Delaying or stopping Prolia without medical guidance can increase bone turnover and may increase the risk of vertebral fractures. A clinician can decide whether another antiresorptive treatment is needed when Prolia is discontinued.
How is Prolia 60 mg injection given?
Prolia is administered under the skin rather than into a vein or muscle. The injection takes a short time, and the syringe is designed for single use.
The injection may be given in the thigh, abdomen, or arm. The upper arm is generally used when another trained person administers the injection. Do not inject into skin that is bruised, tender, red, hard, scarred, or affected by other local skin problems.
The Prolia 60 mg/ml syringe should remain refrigerated according to the product instructions. The syringe may be brought to room temperature before injection, but do not heat the syringe with hot water, a microwave, or another heat source. Do not shake the syringe.
Self-administration should occur only when your healthcare provider has specifically prescribed this approach and provided proper training. Follow the product instructions and use a new syringe for every injection.
Prolia 60 mg side effects
The most common Prolia 60 mg side effects include musculoskeletal pain and pain in an extremity. Other reported reactions include back pain, joint pain, urinary tract infection, upper respiratory tract infection, constipation, abdominal discomfort, rash, eczema, and injection-site reactions.If joint pain persists or becomes troublesome, your healthcare professional can help determine the cause and discuss appropriate joint pain treatment options.
Most side effects do not require emergency care, but persistent, severe, or worsening symptoms require medical advice. The seriousness of a symptom depends on your health history and the clinical context.
Seek urgent medical attention for symptoms of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, hives, wheezing, or difficulty breathing.
Can Prolia cause low calcium levels?
Yes. Prolia can cause hypocalcemia, meaning an abnormally low blood calcium level, and the risk is particularly important in people with advanced kidney disease.
Low calcium can cause muscle cramps, spasms, twitching, tingling or numbness around the mouth or in the fingers and toes, confusion, seizures, weakness, or abnormal heart rhythm. Report these symptoms promptly.
Your healthcare professional should correct hypocalcemia before Prolia treatment begins. Calcium and vitamin D intake is important during therapy, and blood calcium monitoring may be necessary based on your risk factors.
The FDA has issued a boxed warning about severe hypocalcemia in patients with advanced chronic kidney disease, especially people receiving dialysis or those with chronic kidney disease-mineral and bone disorder. Such patients need individualized assessment, appropriate calcium and vitamin D management, and closer monitoring.
Prolia precautions you should discuss with your doctor
Tell your healthcare professional about kidney disease, dialysis, low calcium, vitamin D deficiency, thyroid or parathyroid disorders, malnutrition, dental disease, infections, and previous allergic reactions.
Dental health deserves special attention because Prolia has been associated rarely with osteonecrosis of the jaw, a condition involving damaged jawbone. Tell your doctor about planned tooth extraction, dental surgery, gum disease, loose teeth, or poorly healing mouth sores. Maintain good oral hygiene and attend routine dental care.
Report new or unusual pain in the thigh, hip, or groin. Rare atypical femoral fractures can occur during antiresorptive treatment, and persistent symptoms require clinical assessment.
Tell your healthcare professional about all prescription medicines, over-the-counter medicines, supplements, and other products you use. Do not receive another medicine containing denosumab at the same time as Prolia.
Prolia, pregnancy and breastfeeding
Prolia is contraindicated during pregnancy in the United States because denosumab may cause fetal harm. Pregnancy should be ruled out before administration when pregnancy is possible. Effective contraception is recommended during treatment and for at least 5 months after the last dose.
Tell your healthcare professional if you are pregnant, planning pregnancy, or breastfeeding. The decision about breastfeeding during treatment requires an individualized discussion because available information is limited. These discussions can also be part of broader women’s health considerations, particularly when osteoporosis treatment overlaps with pregnancy planning or other reproductive health needs.
What should you avoid while taking Prolia?
Avoid missed or delayed injections unless your healthcare professional changes the schedule. Do not stop Prolia on your own because stopping or delaying treatment can raise fracture risk.
Avoid receiving another denosumab-containing medicine with Prolia. Prolia contains denosumab, but the products have different approved uses and dosing regimens. Your healthcare professional should determine which denosumab product is appropriate.
Do not ignore symptoms of hypocalcemia, jaw problems, serious infection, allergic reaction, or unusual thigh or groin pain. Prompt assessment can reduce the risk of serious complications.
Do not take calcium or vitamin D at an unsupervised dose. Your clinician can recommend the amount that fits your diet, laboratory results, kidney function, and treatment plan.
What happens if you stop Prolia?
Stopping Prolia requires a medical plan because bone mineral density can decline after discontinuation and the risk of vertebral fractures can increase. Multiple vertebral fractures have been reported after Prolia treatment is stopped.
Your healthcare professional may recommend an alternative antiresorptive medicine after Prolia, depending on your fracture risk and clinical circumstances. Do not schedule your final Prolia injection without discussing the next step.
The ideal total duration of osteoporosis treatment is not identical for every patient. The need for continued denosumab treatment should be reassessed periodically, particularly after several years of therapy.
When should you contact a doctor?
Contact your healthcare professional promptly for severe muscle cramps, tingling, numbness, confusion, seizures, or weakness that could indicate low calcium. Seek urgent care for facial or throat swelling, breathing difficulty, or another severe allergic reaction.
Report fever with a painful, red, swollen, warm area of skin because cellulitis can occur during denosumab treatment. Report jaw pain, swelling, loose teeth, mouth sores that do not heal, or drainage from the mouth. Report persistent hip, thigh, or groin pain because these symptoms can indicate an atypical femoral fracture.
Prolia monitoring and storage
Before each dose, the clinician may review calcium status, kidney function, dental health, fracture risk, medicines, and the timing of the injection. These checks help identify conditions that can change denosumab safety.
Store the pre-filled syringe according to the label, refrigerated at 2°C to 8°C (36°F to 46°F). Protect the syringe from light and do not freeze the syringe. Follow product instructions for room-temperature storage and disposal. Do not use an expired, cloudy, discolored, or damaged syringe.
If you are considering Prolia, discuss your fracture history, bone density results, kidney function, dental status, calcium and vitamin D intake, and medicines with your prescriber.
Frequently Asked Questions
What are the benefits of Prolia injections?
Prolia injections reduce bone breakdown and help maintain or improve bone mineral density in adults with approved osteoporosis or bone-loss indications. Prolia can reduce fracture risk in high-risk patients when used at the prescribed 60 mg dose every 6 months.
What is the most common side effect of Prolia?
The most common Prolia side effects are musculoskeletal pain and pain in an extremity. Back pain and joint pain can occur as well. Tell your healthcare professional about severe, persistent, or worsening pain so the cause can be evaluated.
How many years can I take a Prolia injection?
There is no single maximum number of years that applies to every patient. Treatment duration depends on fracture risk, benefits, adverse effects, and alternatives. Your doctor should periodically reassess continued Prolia therapy, particularly after several years.
Can Prolia be given daily?
No. Prolia is not a daily injection. The standard osteoporosis regimen is 60 mg as one subcutaneous injection once every 6 months. Do not change the frequency because denosumab dosing requires a planned interval and medical supervision.
Is Prolia injection the same as Xgeva?
No. Prolia and Xgeva contain denosumab, but they have different strengths, dosing schedules, and approved indications. Prolia 60 mg is used every 6 months for specified osteoporosis and bone-loss conditions, while Xgeva is used mainly for oncology-related indications.
